Elevance Health, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elevance Health, Inc. on February 26, 2026, regarding events occurring on that date. The filing addresses executive management changes and reaffirms full-year financial guidance.
Key Financial Metrics and Guidance
The filing does not report historical revenue, profit, cash flow, or debt figures for a specific period. Instead, it provides the following forward-looking guidance for the full year 2026:
- Shareholders' Earnings: Reaffirmed at least $22.30 per diluted share.
- Net Unfavorable Items: Approximately $3.20 per diluted share included in the earnings guidance.
- Adjusted Shareholders' Earnings: Expected to be at least $25.50 per diluted share (excluding net unfavorable items).
- Benefit Expense Ratio: Reaffirmed at 90.2% plus or minus 50 basis points.
Material Changes
Executive Departure: Peter D. Haytaian, Executive Vice President and President of Carelon, will transition out of his role effective May 4, 2026, to devote time to family commitments. This departure is not the result of any disagreement with the Company. Mr. Haytaian will serve as a Special Advisor through December 31, 2026, to ensure an orderly transition.
Outlook, Risks, and Contingencies
Management has reaffirmed its 2026 financial targets despite the leadership change. The filing includes extensive forward-looking statements subject to risks including:
- Trends in healthcare costs, utilization rates, and reduced enrollment.
- Regulatory changes affecting healthcare, insurance, and pharmacy services.
- Cyber-attacks, data security incidents, and technology failures.
- Medicare and Medicaid program risks, including Star Ratings and funding.
- Interest rate volatility and the cost of financing due to substantial indebtedness.
- Competitive pressures and risks associated with mergers and acquisitions.
Investor Verification Checklist
- Verify the timeline and details of the leadership transition for Carelon following Peter D. Haytaian's departure.
- Monitor the company's ability to meet the reaffirmed 2026 adjusted shareholders' earnings target of $25.50 per share.
- Track the benefit expense ratio performance against the 90.2% +/- 50 bps guidance.
- Review subsequent filings for updates on the "net unfavorable items" estimated at $3.20 per share.
- Assess the impact of the Special Advisor role on Carelon's operational continuity through year-end 2026.